Hemogenyx Pharmaceuticals (STU:5HU0) EPS (Basic): €-2.00 (TTM As of Dec. 2025)


STU:5HU0 Hemogenyx Pharmaceuticals PLC STU:5HU0
35 GF Score
Price €8.65
! 2 Warning Signs
View Full Analysis

What is Hemogenyx Pharmaceuticals EPS (Basic)?

Hemogenyx Pharmaceuticals STU:5HU0 -5.46% 35 EPS (Basic) is €-2.00 as of Dec. 2025. GuruFocus rates STU:5HU0 with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

Hemogenyx Pharmaceuticals's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was €-0.33. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.00.

Hemogenyx Pharmaceuticals's EPS (Diluted) for the six months ended in Dec. 2025 was €-0.90. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-2.57.

Hemogenyx Pharmaceuticals's EPS without NRI for the six months ended in Dec. 2025 was €-0.90. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -2.57.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Hemogenyx Pharmaceuticals  (STU:5HU0) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Hemogenyx Pharmaceuticals EPS (Basic) Related Terms

Hemogenyx Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Hemogenyx Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemogenyx Pharmaceuticals EPS (Basic) Chart

Hemogenyx Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.30 -2.30 -2.75 -2.19 -1.95

Hemogenyx Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.36 -1.08 -1.08 -1.67 -0.33
STU:5HU0
35GF Score
Hemogenyx Pharmaceuticals PLC STU:5HU0
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hemogenyx Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Hemogenyx Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-11.158-0)/4.443
=-2.51

Hemogenyx Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-5.437-0)/5.349
=-1.02

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-2.00 mean?
Hemogenyx Pharmaceuticals (STU:5HU0) has a EPS (Basic) of €-2.00 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hemogenyx Pharmaceuticals and its competitors.
Is Hemogenyx Pharmaceuticals' EPS (Basic) too high?
Hemogenyx Pharmaceuticals' current EPS (Basic) is €-2.00. Overall, Hemogenyx Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Hemogenyx Pharmaceuticals' EPS (Basic) compare to VRTX and REGN?
Hemogenyx Pharmaceuticals' EPS (Basic) of €-2.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Hemogenyx Pharmaceuticals and its competitors. Hemogenyx Pharmaceuticals's current EPS (Basic) is €-2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemogenyx Pharmaceuticals stock overvalued right now?
Hemogenyx Pharmaceuticals (STU:5HU0) has a current EPS (Basic) of €-2.00. The current EPS (Basic) is €-2.00. Hemogenyx Pharmaceuticals' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Hemogenyx Pharmaceuticals (STU:5HU0), the current EPS (Basic) is €-2.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemogenyx Pharmaceuticals Business Description

Other Exchanges HEMO:UK
Address 6 Heddon Street, London, GBR, W1B 4BT
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments. The Group has one reportable segment, the discovery, development, and commercialisation of treatments relating to blood and immune system disorders and viral infections, and administrative functions in the United Kingdom. It has its presence in United Kingdom; and United States.
35GF Score

Get the complete analysis for STU:5HU0

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.65
Price